|
| 36658425 | Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. | Nat Med | 2023 |
| 37634013 | Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. | | 2023 |
| 37786705 | Evolutionary fingerprints of EMT in pancreatic cancers. | bioRxiv | 2023 |
| 37625401 | KRAS<sup>G12D</sup> inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8<sup>+</sup> TÂ cells. | Cancer Cell | 2023 |
| 36824971 | Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent manner. | bioRxiv | 2023 |
| 36627494 | Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. | Nature | 2023 |
| 36747713 | Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance. | bioRxiv | 2023 |
| 37186844 | SMARCB1 regulates the hypoxic stress response in sickle cell trait. | Proc Natl Acad Sci U S A | 2023 |
| 37055414 | Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. | Blood Cancer J | 2023 |
| 36689560 | Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. | Clin Cancer Res | 2023 |
| 37226898 | Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. | Clin Transl Med | 2023 |
| 35944232 | Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. | JCO Clin Cancer Inform | 2022 |
| 35705814 | Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. | Nature | 2022 |
| 34529467 | Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. | Science | 2021 |
| 32073931 | Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. | Int J Radiat Biol | 2021 |
| 33745946 | Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. | Gastroenterology | 2021 |
| 34117030 | Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. | Cancer Res | 2021 |
| 34108622 | Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. | Oncogene | 2021 |
| 33839689 | Oncogenic <i>KRAS</i> Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. | Cancer Discov | 2021 |
| 34330913 | PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. | Nat Commun | 2021 |
| 32816843 | BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. | Cancer Discov | 2021 |
| 33123754 | Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. | Cancer Immunol Immunother | 2021 |
| 33158812 | Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. | Cancer Res | 2021 |
| 34518211 | Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. | Cancer Res | 2021 |
| 34857765 | The cytosolic iron-sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors. | NPJ Breast Cancer | 2021 |
| 34732714 | Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. | Nat Commun | 2021 |
| 34777916 | Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma. | Oncoimmunology | 2021 |
| 34885132 | Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. | Cancers (Basel) | 2021 |
| 32787110 | Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R. | Journal of Medicinal Chemistry | 2020 |
| 31852834 | <i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. | Clin Cancer Res | 2020 |
| 32359397 | Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. | Cancer Cell | 2020 |
| 32928921 | Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. | Cancer Res | 2020 |
| 33118821 | Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. | J Med Chem | 2020 |
| 30996079 | Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. | Sci Transl Med | 2019 |
| 31719531 | ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. | Nat Commun | 2019 |
| 31557131 | YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. | JCI Insight | 2019 |
| 30625329 | Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. | Cell Rep | 2019 |
| 30986992 | Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. | Cancers (Basel) | 2019 |
| 30867319 | ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. | Sci Transl Med | 2019 |
| 30918400 | Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. | Nature | 2019 |
| 30753823 | p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. | Cancer Cell | 2019 |
| 31500168 | Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. | Cancers (Basel) | 2019 |
| 31068440 | Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. | Sci Transl Med | 2019 |
| 30726735 | Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. | Cell Rep | 2019 |
| 29496759 | The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. | Clin Cancer Res | 2018 |
| 29892070 | An inhibitor of oxidative phosphorylation exploits cancer vulnerability. | Nat Med | 2018 |
| 30498242 | High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. | Nat Commun | 2018 |
| 30388424 | PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. | Cell Stem Cell | 2018 |
| 29628419 | Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. | Cell Metab | 2018 |
| 29267866 | The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. | J Natl Cancer Inst | 2018 |